Organisation paid for research Program year 2025 Source: CMS Open Payments

The Regents of The University of California

Neither a doctor nor a teaching hospital

Research payments

$34,380,851

3,840 payments

Through program year 2025, The Regents of The University of California is reported as receiving $34,380,851 in research payments, across 3,840 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$6,083,215	917
2024	Research	$7,780,557	1,142
2023	Research	$5,392,737	688
2022	Research	$2,992,048	386
2021	Research	$2,782,896	217
2020	Research	$2,276,657	248
2019	Research	$7,072,740	242

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $5,049,886 75 payments
Genentech, Inc. $3,215,834 157 payments
Daiichi Sankyo Inc. $2,057,638 156 payments
GlaxoSmithKline, LLC. $1,508,610 336 payments
Biogen, Inc. $1,449,043 14 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $1,416,346 36 payments
Pfizer Inc. $1,315,832 206 payments
Argenx US, Inc. $1,284,812 322 payments
ACADIA Pharmaceuticals Inc $921,882 53 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $724,407 12 payments

Studies the money was for Research payments · program years 2019–2025

Phase Ib II Study Evaluating the Efficacy and Safety of Treatment Combinations in HCC Morpheus HCC $2,102,380 36 payments
US observational study of DE oral pellets in patients <12 y $897,339 2 payments
Phase II Study of Checkpoint Inhibition with Anti-PD-1 Alone or Anti-PD-1 in Combination with Intratumoral Poly-ICLC Therapy in Patients with High-Volume, Hormone-Sensitive Metastatic Prostate Cancer Receiving Radiation and Androgen Deprivation Therapy $759,352 8 payments
Ta799-012 $611,899 9 payments
A Trial of Setmelanotide in Acquired Hypothalamic Obesity $603,280 9 payments
First-in-Human, Phase 1,1b, Open-label, Multicenter Study of Bifunctional EGFR,TGF Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors $599,864 3 payments
A Phase Ib Trial of Pembrolizumab MK-3475 and Trametinib Focused on Advanced KRAS Mutant Non-Small Cell Lung Cancer $571,284 4 payments
U3-1402-A-U201 $480,686 18 payments
Protocol 331-201-00080 A Multicenter, Randomized, Double-Blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With Or Without Mixed Features, Associated With Bipolar I Disorder $475,241 1 payment
A Phase I,II study of blinatumomab in combination with pembrolizumab MK-3475 for adults with relapsed or refractory B-lineage acute lymphoblastic leukemia with high bone marrow lymphoblast count $469,340 1 payment

What the money was spent on Research payments · program years 2019–2025

Other $64,573 4 payments
Professional salary support $21,103 1 payment
Patient care $16,305 4 payments
Overhead $14,817 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.